Literature DB >> 31163981

Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals.

Brandon K Bellows1, Natalia Ruiz-Negrón2,3, Kirsten Bibbins-Domingo4, Jordan B King5, Mark J Pletcher4, Andrew E Moran1, Valy Fontil6.   

Abstract

BACKGROUND: The Centers for Disease Control and Prevention's Million Hearts initiative includes an ambitious ≥80% blood pressure control goal in US adults with hypertension by 2022. We used the validated Blood Pressure Control Model to quantify changes in clinic-based hypertension management processes needed to attain ≥80% blood pressure control. METHODS AND
RESULTS: The Blood Pressure Control Model simulates patient blood pressures weekly using 3 key modifiable hypertension management processes: office visit frequency, clinician treatment intensification given uncontrolled blood pressure, and continued antihypertensive medication use (medication adherence rate). We compared blood pressure control rates (using the Seventh Joint National Committee on hypertension targets) achieved over 4 years between usual care and the best-observed values for management processes identified from the literature (1-week return visit interval, 20%-44% intensification rate, and 76% adherence rate). We determined the management process values needed to achieve ≥80% blood pressure control in US adults. In adults with uncontrolled blood pressure, usual care achieved 45.6% control (95% uncertainty interval, 39.6%-52.5%) and literature-based best-observed values achieved 79.7% control (95% uncertainty interval, 79.3%-80.1%) over 4 years. Increasing treatment intensification rates to 62% of office visits with an uncontrolled blood pressure resulted in ≥80% blood pressure control, even when the return visit interval and adherence remained at usual care values. Improving to best-observed values for all 3 management processes would achieve 78.1% blood pressure control in the overall US population with hypertension, approaching the ≥80% Million Hearts 2022 goal.
CONCLUSIONS: Achieving the Million Hearts blood pressure control goal by 2022 will require simultaneously increasing visit frequency, overcoming therapeutic inertia, and improving patient medication adherence. As the relative importance of each of these 3 processes will depend on local characteristics, simulation models like the Blood Pressure Control Model can help local healthcare systems tailor strategies to reach local and national benchmarks.

Entities:  

Keywords:  adults; blood pressure; cardiovascular disease; hypertension; medication adherence

Mesh:

Substances:

Year:  2019        PMID: 31163981      PMCID: PMC6768426          DOI: 10.1161/CIRCOUTCOMES.118.005624

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  46 in total

1.  Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies.

Authors:  William J Elliott; Craig A Plauschinat; Grant H Skrepnek; Douglas Gause
Journal:  J Am Board Fam Med       Date:  2007 Jan-Feb       Impact factor: 2.657

2.  A cross-national study of the persistence of antihypertensive medication use in the elderly.

Authors:  Boris L G van Wijk; William H Shrank; Olaf H Klungel; Sebastian Schneeweiss; M Alan Brookhart; Jerry Avorn
Journal:  J Hypertens       Date:  2008-01       Impact factor: 4.844

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

5.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

6.  Failure to intensify antihypertensive treatment by primary care providers: a cohort study in adults with diabetes mellitus and hypertension.

Authors:  Shari Danielle Bolen; T Alafia Samuels; Hsin-Chieh Yeh; Spyridon S Marinopoulos; Maura McGuire; Marcela Abuid; Frederick L Brancati
Journal:  J Gen Intern Med       Date:  2008-01-25       Impact factor: 5.128

7.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28

8.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

9.  Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting.

Authors:  Jennifer Wogen; Charles A Kreilick; Richard C Livornese; Krista Yokoyama; Feride Frech
Journal:  J Manag Care Pharm       Date:  2003 Sep-Oct

10.  Visit frequency and hypertension.

Authors:  Richard Guthmann; Nancy Davis; Matthew Brown; Jose Elizondo
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-06       Impact factor: 3.738

View more
  13 in total

Review 1.  Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care.

Authors:  Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress
Journal:  Curr Hypertens Rep       Date:  2019-11-07       Impact factor: 5.369

2.  Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018.

Authors:  Paul Muntner; Shakia T Hardy; Lawrence J Fine; Byron C Jaeger; Gregory Wozniak; Emily B Levitan; Lisandro D Colantonio
Journal:  JAMA       Date:  2020-09-22       Impact factor: 56.272

3.  [Drivers and scorecards to improve hypertension control in primary care practice: Recommendations from the HEARTS in the Americas Innovation GroupFactores impulsores y métodos de puntuación para mejorar el control de la hipertensión en la práctica clínica de la atención primaria: recomendaciones del grupo de innovación de HEARTS en las Américas].

Authors:  Jeffrey W Brettler; Gloria P Giraldo Arcila; Teresa Aumala; Allana Best; Norm Rc Campbell; Shana Cyr; Angelo Gamarra; Marc G Jaffe; Mirna Jimenez De la Rosa; Javier Maldonado; Carolina Neira Ojeda; Modesta Haughton; Taraleen Malcolm; Vivian Perez; Gonzalo Rodriguez; Andres Rosende; Yamile Valdes Gonzalez; Peter W Wood; Eric Zuniga; Pedro Ordunez
Journal:  Rev Panam Salud Publica       Date:  2022-05-10

Review 4.  Cost-Effectiveness of Recommendations From the Surgeon General's Call-to-Action to Control Hypertension.

Authors:  Gabriel S Tajeu; Stavros Tsipas; Michael Rakotz; Gregory Wozniak
Journal:  Am J Hypertens       Date:  2022-03-08       Impact factor: 3.080

5.  Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018.

Authors:  Alexander R Zheutlin; Catherine G Derington; Jordan B King; Ransmond O Berchie; Jennifer S Herrick; Dave L Dixon; Jordana B Cohen; Daichi Shimbo; Ian M Kronish; Joseph J Saseen; Paul Muntner; Andrew E Moran; Adam P Bress
Journal:  Am Heart J       Date:  2021-10-16       Impact factor: 5.099

6.  Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops.

Authors:  Kelsey B Bryant; Andrew E Moran; Dhruv S Kazi; Yiyi Zhang; Joanne Penko; Natalia Ruiz-Negrón; Pamela Coxson; Ciantel A Blyler; Kathleen Lynch; Laura P Cohen; Gabriel S Tajeu; Valy Fontil; Norma B Moy; Joseph E Ebinger; Florian Rader; Kirsten Bibbins-Domingo; Brandon K Bellows
Journal:  Circulation       Date:  2021-04-15       Impact factor: 39.918

7.  Association of Differences in Treatment Intensification, Missed Visits, and Scheduled Follow-up Interval With Racial or Ethnic Disparities in Blood Pressure Control.

Authors:  Valy Fontil; Lucia Pacca; Brandon K Bellows; Elaine Khoong; Charles E McCulloch; Mark Pletcher; Kirsten Bibbins-Domingo
Journal:  JAMA Cardiol       Date:  2022-02-01       Impact factor: 30.154

8.  Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Alexander R Zheutlin; Favel L Mondesir; Catherine G Derington; Jordan B King; Chong Zhang; Jordana B Cohen; Dan R Berlowitz; D Edmund Anstey; William C Cushman; Tom H Greene; Olugbenga Ogedegbe; Adam P Bress
Journal:  JAMA Netw Open       Date:  2022-01-04

9.  Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control.

Authors:  Kelsey B Bryant; James P Sheppard; Natalia Ruiz-Negrón; Ian M Kronish; Valy Fontil; Jordan B King; Mark J Pletcher; Kirsten Bibbins-Domingo; Andrew E Moran; Richard J McManus; Brandon K Bellows
Journal:  J Am Heart Assoc       Date:  2020-07-22       Impact factor: 5.501

10.  Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study.

Authors:  Hemanshu Das; Andrew E Moran; Anupam K Pathni; Bhawna Sharma; Abhishek Kunwar; Sarang Deo
Journal:  Glob Heart       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.